Conflicts of Interest policy – New York Times Sun, 28 Mar 2004 To: ‘Executive-editor@nytimes’; ‘gcollins@nytimes’; ‘arosenthal@nytimes’; ‘pboffey@nytimes’; ‘lchang@nytimes’; ‘oped@nytimes’ Cc: ‘Daniel Okrent’ ALLIANCE FOR HUMAN RESEARCH PROTECTION (AHRP) Promoting openness and full disclosure https://ahrp.org FYI Friday’s New York Times included the following Editor’s Note on the paper’s Op Ed page:…
Recycled drugs: failed antidepressants– Stratera marketed for ADHD; Cymbalta for incontinence Mon, 26 Apr 2004 A front page article in The Wall Street Journal (excerpt below) provides a roadmap of failed Eli Lilly drugs which the company repackaged for a different condition than the one for which the drugs had…
Additional information as of late Wed Oct 19: Although I was assured that attendance for a presentation by Dr. David Healy (at Columbia University School of Public Health on Oct. 20 at 12:30) would be open to the public, a problem seems to have emerged after an AHRP Infomail about…
Despite Vow, Drug Makers Still Wtihhold Data – NYT letters Thu, 9 Jun 2005 An important article by Alex Berenson in The New York Times, “Despite Vow, Drug Makers Still Withhold Data,” corroborated the untrustworthiness of drug manufacturers. Their public pronouncements and promises to fully disclose their clinical trial data-including…
Opinion column: Antidepressants Carry Risk– Dr. Joseph Glenmullen Sat, 5 Mar 2005 A hard corps of influential mental health professionals continue to mislead the public‹parents in particular–about the very real and proven risks of antidepressant drugs. In some people‹especially youngsters‹antidepressants have triggered violent and suicidal behavior. Because of the compelling…
AHRP Position Statement on Mental Health Screening – FDA Hearing Re: Drug Advertising Wed, 02 Nov 2005 FDA is holding public hearings (Nov 1, 2) Re: Direct-to-Consumer Promotion of Medical Products at: National Transportation Safety Board Boardroom and Conference Center 429 L’Enfant Plaza, SW., Washington, DC 2 Time: 9:00 –5:00….
September 6, 2002. Dr. Arif Kahn analysis of Psych Drug Trials Reveals High Suicide risk. FYI Clinical Psychiatry News online reports (below) that an independent analysis of the suicide rate in psychotropic drug trials– for drugs approved by the FDA between 1985-2000– found that the NEW DRUGS did NOT REDUCE…
Jan 22, 1999 SCIENCE Volume 283, Number 5401, 22 Jan 1999, pp. 464 – 465 BIOETHICS NIMH to Screen Studies for Science and Human Risks Eliot Marshall For more than a year, patient activists and ethicists have been calling for a revolution in the way clinical studies in psychiatry are…
THE IMPACT OF THE FDA MODERNIZATION ACT ON THE RECRUITMENT OF CHILDREN FOR RESEARCH Vera Hassner Sharav Published in ETHICAL HUMAN SCIENCES & SERVICES Summer 2003, vol. 5 pp. 83-108 Abstract This paper argues that contrary to the claims made by the research stakeholders in industry, academia and government, the…
Eugenics: the California connection to Nazi policies_SF Chronicle Mon, 10 Nov 2003 On Sunday, Nov 9, the San Francisco Chronicle published an extraordinary, most informative article by Edwin Black, that sheds light on the role played by the American eugenics movement in the Nazi extermination policy. Eugenics is a pseudoscience…
Psychiatry’s Claims Re: Brain Imaging Have Far Outpaced Science – NYT Tue, 18 Oct 2005 A front page report in The New York Times Science section pulls the rug out from yet another of psychiatry’s myths. Benedict Carey reports: “Not long ago, scientists predicted that these images, produced by sophisticated…
Broken Brains or Flawed Studies? Thu, 24 Jul 2003 Broken Brains or Flawed Studies? A critical review of ADHD imaging studies by Jonathan Leo, Ph.D and David Cohen, Ph.D methodically demonstrates how scientifically flawed methodology undermines the integrity and claimed findings of over 30 imaging studies that are the basis…
